A team of researchers at the University of Utah Huntsman Cancer Institute reports that an innovative pathway-targeted therapy may be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease.
Dr. Martin McMahon, senior director of preclinical translation at the Huntsman Cancer Institute and professor of dermatology in the United States, evaluated an investigational compound for the drug daraxonelasib. NRAS-Driven melanoma. NRAS– Propulsive melanoma is an aggressive type of skin cancer caused by mutations in the skin. NRAS gene. Daraxonrasib, developed by Revolution Medicines, targets and inhibits RAS, a protein that when altered causes cancer. NRAS is a subtype of R.A.S. It is mutated in about a quarter of melanoma cases.
Dalaxone lasib’s results as a treatment for metastatic pancreatic cancer, which doubled patients’ life expectancy in a Phase 3 clinical trial, recently received a standing ovation from thousands of physicians at the American Society of Clinical Oncology annual meeting. Huntsman Cancer Institute was one of only 60 hospitals worldwide to offer that clinical trial (RASolute 302).
Daraxone lasib’s remarkable success in treating pancreatic cancer indicates that we have entered the era of treating even the most resistant cancers. R.A.S.– The cancer that causes it is treatable. Our data strongly support the potential for future clinical utility in treating patients with: NRAS– Malignant melanoma due to dalaxone lasib.”
Dr. Martin McMahon, Senior Director of Preclinical Translation, Huntsman Cancer Institute, Professor of Dermatology, University of Utah
Mr. McMahon and his team R.A.S. Inhibitors in many preclinical models, including melanoma samples from patients. The research results are cancer researchJournal of the American Association for Cancer Research.
“All about us NRAS-The driven model was very sensitive to this R.A.S. inhibitor. In fact, contractions are extremely rare. NRAS“It’s exciting to think that these results could lead to new treatments to help patients overcome their disease,” said Dr. Mona Foss, a research scientist at Huntsman Cancer Institute and lead author of the publication.
Melanoma is the deadliest skin cancer, and their research aims to fill an unmet clinical need in patients with metastatic disease. These patients usually receive immunotherapy, which harnesses the patient’s own immune system, as the earliest treatment. Immunotherapy has revolutionized the treatment of metastatic melanoma. Foss says the treatment is effective in about half of melanoma patients, with deep and long-lasting responses in some cases.
If immunotherapy fails or becomes less effective, doctors turn to targeted therapy as second-line treatment. Targeted therapies attack cancer proteins and their effectors to kill cancer cells or slow their growth.
“Patients with other mutations such as BRAF Clinically approved second-line treatments are available. However, the following patients NRASDr. McMahon said, “Malignant melanoma lacks effective targeted therapies to treat the cancer. Dalaxone lasib is a targeted therapy that may provide new treatments and hope for patients suffering from this devastating disease.”
The researchers also observed that some of the models developed drug resistance, as often happens with patients receiving pathway-targeted therapies. Resistance to dalaxone lasib is caused by mitogen-activated protein kinase (MEK1), a protein downstream of RAS, or loss of expression of cyclophilin A, a chaperone protein required for the inhibitory effect of dalaxone lasib on RAS proteins.
“Further research is needed to build on the backbone of daraxone lasib and find drug combinations that increase the depth and durability of response in melanoma patients,” says McMahon.
McMahon and Foss hope the drug will move into clinical trials for patients who are not candidates for immunotherapy or for whom immunotherapy has not responded.
“This study reflects the power of Huntsman Cancer Institute’s integrated approach, where laboratory discovery, translational research, and clinical trials come together to accelerate progress for patients,” said Neri Ulrich, Ph.D., M.S., executive director of the Comprehensive Cancer Center, chief scientific officer of Huntsman Cancer Institute, John and Karen Huntsman Professor of Cancer Research, and professor of Population Health Sciences. Melanoma is most important in Utah and the Mountain West region where melanoma is a very common cancer. ”
The important research conducted every day at Huntsman Cancer Institute is supported by the National Institutes of Health/National Cancer Institute, including Cancer Center Support Grant P30 CA042014 and the Huntsman Cancer Foundation.
sauce:
University of Utah Huntsman Cancer Institute
Reference magazines:
Foss, M. others. (2026). Genetic factors of susceptibility or resistance to RAS(ON) multiselective inhibitors NRAS – Mutated melanoma. cancer research. DOI: 10.1158/0008-5472.can-26-1313. https://aacrjournals.org/cancerres/article-abstract/doi/10.1158/0008-5472.CAN-26-1313/785950/Genetic-Drivers-of-Sensitivity-or-Resistance-to
